I
Exchange
—
Entity type
operating
Fiscal year end
Apr 26
Headquarters
DE
Recent Filings
- 8-K165.9 KBIPI Legacy Liquidation CoMar 12, 8:43 AM ET·0001193125-24-065453
- 8-K154.1 KBIMPEL PHARMACEUTICALS INCFeb 14, 5:15 PM ET·0001193125-24-036588
- 8-K403.0 KBIMPEL PHARMACEUTICALS INCJan 2, 4:23 PM ET·0001193125-24-000705
- 8-K647.2 KBIMPEL PHARMACEUTICALS INCDec 20, 6:08 AM ET·0001193125-23-299243
- 8-K153.2 KBIMPEL PHARMACEUTICALS INCDec 18, 8:31 AM ET·0001193125-23-297146
- SC 13D/A754.8 KBIMPEL PHARMACEUTICALS INCDec 4, 5:12 PM ET·0001140361-23-056192
- 8-K148.5 KBIMPEL PHARMACEUTICALS INCDec 4, 6:05 AM ET·0001193125-23-287903
- SC 13D/A723.4 KBIMPEL PHARMACEUTICALS INCNov 15, 4:06 PM ET·0001140361-23-053430
- 10-Q9.0 MBIMPEL PHARMACEUTICALS INCNov 14, 4:27 PM ET·0000950170-23-063759
- 8-K213.5 KBIMPEL PHARMACEUTICALS INCNov 14, 4:01 PM ET·0001193125-23-277083
Insiders
10- 5AM Opportunities I (GP), LLC10% Owner
- 5AM Opportunities I, L.P.10% Owner
- 5AM Ventures V, L.P.10% Owner
- ADAMS ADRIANDirector, COB, CEO and President
- Adelman Robert J10% Owner
- Allison David D.Director
- Amin RajivVP, Controller & Interim CFO
- BAM Partners Trust10% Owner
- BROOKFIELD Corp /ON/10% Owner
- Brookfield Oaktree Holdings, LLC10% Owner
Tickers
No tickers on record
Addresses
business
201 ELLIOTT AVE. W SUITE 260
SEATTLE, WA, 98119
mailing
201 ELLIOTT AVE. W SUITE 260
SEATTLE, WA, 98119
Former Names
- IMPEL PHARMACEUTICALS INC2024-02-15
- IMPEL NEUROPHARMA INC2022-04-14